Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd manufactures Bulk Drugs and Intermediaries.
- Market Cap ₹ 261 Cr.
- Current Price ₹ 73.9
- High / Low ₹ 87.5 / 31.9
- Stock P/E
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE -27.6 %
- ROE -16.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 94.4 to 64.7 days.
Cons
- Stock is trading at 3.88 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -0.37%
- Promoter holding is low: 5.19%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|
| 4 | 0 | 15 | 16 | |
| 4 | 10 | 28 | 30 | |
| Operating Profit | 0 | -10 | -13 | -14 |
| OPM % | 3% | -87% | -89% | |
| 0 | 0 | 1 | 1 | |
| Interest | 0 | 0 | 2 | 1 |
| Depreciation | 0 | 0 | 2 | 2 |
| Profit before tax | 0 | -10 | -16 | -16 |
| Tax % | 0% | -24% | -24% | |
| 0 | -8 | -12 | -13 | |
| EPS in Rs | 0.15 | -3.52 | -2.26 | -3.50 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -32% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 39% |
| 5 Years: | 72% |
| 3 Years: | 66% |
| 1 Year: | 81% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 10 | 21 | 35 | 35 |
| Reserves | -2 | 1 | 37 | 32 |
| 0 | 0 | 9 | 14 | |
| 2 | 2 | 11 | 13 | |
| Total Liabilities | 11 | 25 | 91 | 95 |
| 0 | 0 | 63 | 69 | |
| CWIP | 0 | 2 | 7 | 3 |
| Investments | 0 | 3 | 0 | 0 |
| 11 | 19 | 21 | 22 | |
| Total Assets | 11 | 25 | 91 | 95 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -0 | -4 | -11 | |
| 0 | -5 | -75 | |
| 0 | 21 | 78 | |
| Net Cash Flow | 0 | 12 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 124 | 65 | |
| Inventory Days | 91 | 0 | 114 |
| Days Payable | 236 | 163 | |
| Cash Conversion Cycle | -21 | 16 | |
| Working Capital Days | -18 | -9 | |
| ROCE % | -64% | -28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Listing Regulations, 2015, enclosed herewith the copies of newspaper publications providing extracts of unaudited financial results for the quarter and half year ended on September …
-
Announcement Under Regulation 30 - Contact Details Of KMP For Determining Materiality Of Event/ Information And Making Disclosure.
13 Nov - Change in contact details of KMP.
-
Financial Results For The Quarter And Half Year Ended September 30, 2024
13 Nov - Approval of unaudited financial results for Q2 2024.
-
Board Meeting Outcome for Board Meeting Outcome For Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2024.
13 Nov - Approval of unaudited financial results for Q2 2024.
-
Announcement Under Regulation 30 (LODR) - Intimation On Loan Agreement.
9 Nov - Company enters loan agreement for Rs 12.5 Crore.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Specialty Chemicals:[1] Retinol, DL Alpha Tocopherol, D-Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10, D-Biotin
b) Skin Care:[2] Best care hands, Hands Sanitizer, Moisturizing Cream, Skin-Sure Plus, Skin-Sure Ultra, Alcohol Gel, Barrier Cream
c) Hospital Care:[3] Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen-G, Strumen TRIACID, Facein Eco, Facein Power, Facein Spray, Sod Hypochlorite, Wipes, PPE
d) Generics:[4] Linzomust, Ceforoot 1.5g, Trendyclav-L, Cobasure Gold 2ML INJ, Benfoshine, Amplimmune, Thiaxa T8, Molprime SR, Citibrain-Plus, Duojoint